Three-component reaction of azulene, aryl glyoxal and 1,3dicarbonyl compound for the synthesis of various azulene derivatives

Gong Jing,^a Anatoly A. Peshkov,^b Jiafeng Yu,^a Sagadat Amandykova,^b Aidana Gimnkhan,^b Jianjun Huang,^a Stepan Kashtanov,^c Olga P. Pereshivko^{*,a,b} and Vsevolod A. Peshkov^{*,a,b,d}

Table of content

This page	1
X-ray crystallographic analysis	2
Synthesis and characterization	6
UV/vis absorption spectra	20
Copies of ¹ H and ¹³ C NMR spectra	28-85

^{a.} College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Dushu Lake Campus, Suzhou, 215123, P.R. China. email: olga@suda.edu.cn; vsevolod@suda.edu.cn

^{b.} Department of Chemistry, School of Sciences and Humanities, Nazarbayev University, 53 Kabanbay Batyr Ave, Block 7, Nur-Sultan 010000, Republic of Kazakhstan. email: olga.pereshivko@nu.edu.kz; vsevolod.peshkov@nu.edu.kz

^{c.} Department of Chemistry, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, P.R. China.

^{d.} The Environment and Resource Efficiency Cluster (EREC), Nazarbayev University, Nur-Sultan, Republic of Kazakhstan.

X-ray crystallographic analysis

General details

Single crystals of **7b** were obtained by slow evaporation from dimethylformamide. The images were interpreted and integrated with the program Diamond v.4.0 (Crystal Impact).¹ Using Olex2,² the structures were solved with the ShelXS³ structure solution program using direct methods and refined by full-matrix least-squares on F^2 with the ShelXL⁴ refinement package.

Crystal data for 7b



Molecular structure of **7b**, showing thermal displacement ellipsoids at the 50% probability level; the dimethyl formamide (DMF) molecule acquired during the crystallization process and present in the crystal packing is not shown

Crystal data for 7b·*DMF*. $C_{32}H_{27}NO \cdot C_{3}H_{7}NO$, M = 514.64 g/mol, triclinic, space group P-1 (no. 2), a =

¹ Diamond - Crystal and Molecular Structure Visualization Crystal Impact - Dr. H. Putz & Dr. K. Brandenburg GbR, Kreuzherrenstr. 102, 53227 Bonn, Germany http://www.crystalimpact.com/diamond.

² O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Cryst.*, 2009, **42**, 339.

³ G. M. Sheldrick, Acta Cryst. A, 2008, 64, 112.

⁴ G. M. Sheldrick, Acta Cryst. C, 2015, **71**, 3.

10.9118(6) Å, b = 11.6167(6) Å, c = 13.1533(7) Å, V = 1363.93(13) Å³, Z = 27, T = 296.15 K, μ (MoK α) = 0.077 mm⁻¹, *Dcalc* = 1.253 g/cm³, 64042 reflections measured (4.878° $\leq 2\Theta \leq 55.058°$), 6259 unique ($R_{int} = 0.0882$, $R_{sigma} = 0.0494$) which were used in all calculations. The final R_1 was 0.0450 (I > 2 σ (I)) and wR_2 was 0.1000 (all data).

Structural features:

- the unit cell contains two molecules of the compound ($C_{32}H_{27}NO$) along with two molecules of solvent ($C_{3}H_{7}NO$, dimethylformamide (DMF))



Composition of the unit cell of 7b



Packing diagram of the crystal structure of 7b, viewed down the crystallographic a-axis.



Packing diagram of the crystal structure of **7b**, viewed down the crystallographic b-axis.



Packing diagram of the crystal structure of **7b**, viewed down the crystallographic c-axis.

Synthesis and characterization

General information

Unless otherwise specified, the starting materials and solvents were purchased from commercial sources and used as received. Azulene-1-carbaldehyde⁵ and ethyl azulene-1-carboxylate⁶ were synthesized following previously described protocols. Aryl glyoxal hydrates **2** were purchased or synthesized following previously described protocol.⁷ Melting points were measured using INESA WRR apparatus. NMR spectra were recorded using 400 MHz Bruker Avance instruments. The ¹H and ¹³C chemical shifts are reported relative to TMS using the residual CDCl₃ or [D₆]DMSO signal as internal reference. HRMS were performed on a Bruker microTOF-Q III. UV-visible absorption spectra were recorded using Agilent Technologies Cary Series UV-VIS-NIR Spectrophotometer.

Screening of the reaction conditions for the synthesis of azulene derivative 4a



Entry	1a:2a:3a ratio	Solvent	Time (h)	Isolated yield (%)
1	1:1:1	MeOH	1	63
2	1:1:1	iPrOH	1	74
3	1:1.2:1.2	iPrOH	1	78
4	1:1.2:1.2	iPrOH	0.5	84
5	1:1:1	DMF	0.5	58
6	1:1:1	<i>t</i> BuOH	0.5	76
7	1:1:1	CF ₃ CH ₂ OH	0.5	-

⁵ A. Székely, Á. Péter, K. Aradi, G. L. Tolnai and Z. Novák, Org. Lett., 2017, 19, 954.

⁶ J. Dubovik and A. Bredihhin, *Synthesis*, 2015, 47, 538.

⁷ (a) P. Wang, W.-J. Tao, X.-L. Sun, S. Liao and Y. Tang, *J. Am. Chem. Soc.*, 2013, **135**, 16849; (b) H. Batchu and S. Batra, *Eur. J. Org. Chem.*, 2012, 2935; (c) G.-X. He, J.-M. Yuan, H.-M. Zhu, K. Wei, L.-Y. Wang, S.-L. Kong, D.-L. Mo, C.-X. Pan and G.-F. Su, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 1660; (d) G. Fodor and Ö. Kovacs, *J. Am. Chem. Soc.*, 1949, **71**, 1045.

Synthesis of azulene derivatives 4 *via* three-component reaction of azulene 1, aryl glyoxal 2 and 1,3-dicarbonyl compound 3

General procedure A

Arylglyoxal monohydrate 2 (0.48 mmol, 1.2 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (2 mL) followed by addition of azulene 1 (0.4 mmol, 1 equiv) and 1,3-dicarbonyl compound 3 (0.48 mmol, 1.2 equiv). The resulting mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 30 min. After completion of reaction, the resulting mixture was diluted with ethyl acetate. Then silica gel was added and the volatiles were removed under reduced pressure. Column chromatography with petroleum ether/EtOAc (the ratio was adjusted according to TLC) as eluent delivered azulene derivative 4.

General procedure B

Arylglyoxal monohydrate **2** (0.3 mmol, 1.5 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of azulene **1** (0.2 mmol, 1 equiv) and 1,3-dicarbonyl compound **3** (0.4 mmol, 2 equiv). The resulting mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 1h. Upon completion, the mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (the ratio was adjusted according to TLC) as eluent delivered azulene derivative **4**.



5-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4a). Yield: 67 mg, 84% (Procedure A, 0.2 mmol scale); purple solid; mp: 151-152°C; ¹H NMR (400 MHz, CDCl₃) \delta 8.54 (d,** *J* **= 9.5 Hz, 1H), 8.32 (d,** *J* **= 9.2 Hz, 1H), 7.80 – 7.55 (m, 4H), 7.47 – 7.15 (m, 6H), 6.46 (s, 1H), 3.84 (s, 1H), 3.33 (s, 3H), 3.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 198.5, 168.1, 167.6, 151.7, 141.5, 140.7, 137.9, 137.2, 135.1, 134.9, 133.5, 131.8, 129.4, 128.6, 124.1, 123.7, 123.1, 117.5, 51.0, 50.4, 29.0, 28.7; HRMS (ESI, [M+Na]⁺) for C₂₄H₂₀N₂O₄Na⁺ calcd. 423.1315, found 423.1287.**



5-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)pyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4b). Yield: 134 mg, 90% (Procedure A, 0.4 mmol scale, column chromatography was conducted using CH₂Cl₂/MeOH (9:1) as eluent); dark grey-blue solid; mp: 151-153°C; ¹H NMR (400 MHz, [D₆]DMSO) \delta 8.98 (s, 2H), 8.47 (d,** *J* **= 9.8 Hz, 1H), 8.24 (d,** *J* **= 9.2 Hz, 1H), 8.11 (d,** *J* **= 3.8 Hz, 1H), 7.98 – 7.90 (m, 2H), 7.58 – 7.43 (m,**

2H), 7.41 – 7.34 (m, 2H), 7.29 (d, J = 3.8 Hz, 1H), 7.11 – 6.99 (m, 2H), 6.15 (s, 1H), 3.35 (s, 1H, tentatively overlaped with signal of water); ¹³C NMR (100 MHz, [D₆]DMSO) δ 200.4, 163.6, 151.8, 140.4, 140.3, 138.4, 136.6, 135.2, 133.5, 131.4, 131.3, 127.7, 121.6, 121.0, 116.2, 89.3, 42.0, one signal is tentatively overlapped with the signal of [D₆]DMSO; HRMS (ESI, [M+Na]⁺) for C₂₂H₁₆N₂O₄Na⁺ calcd. 395.1002, found 395.1002.



2-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)-3-hydroxycyclohex-2-en-1-one (4c). Yield: 46 mg, 65% (Procedure B, 0.2 mmol scale); dark blue solid; mp: 80-82°C; ¹H NMR (400 MHz, CDCl₃) δ 11.13 (bs, 1H), 8.45 (d, *J* = 9.6 Hz, 1H), 8.32 – 3.22 (m, 3H), 7.92 (d, *J* = 3.9 Hz, 1H), 7.64 – 7.54 (m, 2H), 7.52 – 7.44 (m, 2H), 7.41 (s, 1H), 7.30 (d, *J* = 3.8 Hz, 1H), 7.21 – 7.08 (m, 2H), 2.60 – 2.30 (m, 4H), 1.99 – 1.77 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 205.6, 197.2, 177.1, 141.2, 138.1, 137.2, 136.7, 136.4, 136.0, 134.6, 134.3, 129.7, 129.1, 124.6, 123.3, 123.1, 117.0, 113.7, 39.7, 36.8, 30.6, 20.4; HRMS (EI, [M+Na]⁺) for C₂₄H₂₀O₃Na⁺ calcd. 379.1305, found 379.1306.



2-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)-3-hydroxy-5,5-dimethylcyclohex-2-en-1-one (4d). Yield: 267 mg, 69% (Procedure A, 1 mmol scale); black-blue solid; mp: 150-152°C; ¹H NMR (400 MHz, CDCl₃) δ 10.80 (s, 1H), 8.40 (d, J = 9.7 Hz, 1H), 8.30 – 8.22 (m, 3H), 7.89 (d, J = 3.9 Hz, 1H), 7.64 – 7.52 (m, 2H), 7.52 – 7.44 (m, 2H), 7.35 (s, 1H), 7.30 (d, J = 3.8 Hz, 1H), 7.18 –7.08 (m, 2H), 2.43 (d, J = 17.7 Hz, 1H), 2.37 – 2.23 (m, 3H), 1.03 (s, 3H), 0.91 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 205.3, 196.8, 175.3, 141.3, 138.1, 137.2, 136.7, 136.4, 136.0, 134.6, 134.3, 129.7, 129.1, 124.5, 123.3, 123.1, 117.0, 112.7, 50.6, 44.1, 39.8, 31.6, 29.4, 27.1; HRMS (EI, [M+Na]⁺) for C₂₆H₂₄O₃Na⁺ calcd. 407.1618, found 407.1618.



4-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2H)-one (4e). Yield: 95 mg, 37% (Procedure A, 0.6 mmol scale, column chromatography was conducted using CH_2Cl_2 /petroleum ether (1:1) as eluent, after which the product was washed with hexane); black-blue solid; mp: 70-72°C; in NMR, observed as as a mixture of two interconvertible diastereomeric enol forms

(dr = 2:1); ¹H NMR (400 MHz, CDCl₃) δ 11.53 (s, 0.67H), 10.92 (s, 0.33H), 8.54 (d, *J* = 9.6 Hz, 0.67H), 8.41 (d, *J* = 9.7 Hz, 0.33H), 8.33 – 8.20 (m, 3H), 7.95 (d, *J* = 3.3 Hz, 0.67H), 7.87 (d, *J* = 3.4 Hz, 0.33H), 7.66 – 6.94 (m, 13H), 3.34 – 3.29 (m, 0.33H), 3.27 – 3.09 (m, 0.67H), 2.86 – 2.50 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 205.8, 205.0, 196.3, 196.1, 176.3, 176.8, 142.6, 141.30, 141.28, 138.2, 138.1, 137.29, 137.26, 136.7, 136.4, 136.0, 134.7, 134.6, 134.4, 134.3, 129.8, 129.7, 129.1, 128.9, 128.7, 127.1, 127.0, 126.8, 126.7, 124.4, 124.2, 123.41, 123.38, 123.3, 117.1, 113.7, 113.5, 43.8, 43.6, 39.9, 39.7, 38.34, 38.29, 38.25, 37.5; HRMS (EI, [M+H]⁺) for C₃₀H₂₅O₃⁺ calcd. 433.1798, found 433.1797.



2-(1-(Azulen-1-yl)-2-oxo-2-phenylethyl)cycloheptane-1,3-dione (4f). Yield: 135 mg, 91% (Procedure A, 0.4 mmol scale); purple solid; mp: 170-172°C; ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 9.8 Hz, 1H), 8.18 (d, *J* = 9.4 Hz, 1H), 7.98 – 7.86 (m, 2H), 7.76 (d, *J* = 3.8 Hz, 1H), 7.65 – 7.54 (m, 1H), 7.38 – 7.29 (m, 2H), 7.28 – 7.19 (m, 3H), 7.16 – 7.07 (m, 1H), 6.24 (d, *J* = 10.5 Hz, 1H), 5.55 (d, *J* = 10.5 Hz, 1H), 3.02 – 2.88 (m, 1H), 2.57 – 2.45 (m, 1H), 2.37 – 2.11 (m, 4H), 1.88 – 1.67 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 204.2, 203.0, 198.9, 141.9, 138.2, 137.2, 136.8, 136.7, 136.0, 134.7, 132.8, 128.7, 128.5, 123.7, 123.4, 123.0, 117.7, 71.0, 45.4, 44.6, 24.5, 24.1; HRMS (EI, [M+Na]⁺) for C₂₅H₂₂O₃Na⁺ calcd. 393.1461, found 393.1461.



5-(1-(Azulen-1-yl)-2-(4-bromophenyl)-2-oxoethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4g).** Yield: 388 mg, 81% (Procedure A, 1 mmol scale); black-blue solid; mp: 171-172°C; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 9.7 Hz, 1H), 8.34 (d, *J* = 9.4 Hz, 1H), 7.75 – 7.65 (m, 1H), 7.62 (d, *J* = 3.9 Hz, 1H), 7.53 (d, *J* = 8.5 Hz, 2H), 7.41 – 7.20 (m, 5H), 6.39 (d, *J* = 2.5 Hz, 1H), 3.84 (d, *J* = 2.5 Hz, 1H), 3.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.5, 167.9, 167.4, 151.6, 141.5, 140.6, 138.0, 137.3, 135.0, 133.87, 131.85, 131.80, 130.8, 128.7, 124.3, 123.3, 123.2, 117.6, 51.0, 50.2, 29.0, 28.7; HRMS (EI, [M+Na]⁺) for C₂₄H₁₉BrN₂O₄Na⁺ calcd. 501.0420, found 501.0408.



5-(1-(Azulen-1-yl)-2-(4-fluorophenyl)-2-oxoethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4h).** Yield: 136 mg, 81% (Procedure A, 0.4 mmol scale); purple solid; mp: 151-152°C; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 9.7 Hz, 1H), 8.34 (d, *J* = 9.4 Hz, 1H), 7.76 – 7.66 (m, 3H), 7.64 (d, *J*) = 4.0 Hz, 1H), 7.37 – 7.21 (m, 3H), 6.95 – 6.83 (m, 2H), 6.41 (d, J = 2.5 Hz, 1H), 3.83 (d, J = 2.6 Hz, 1H), 3.34 (s, 3H), 3.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 196.9, 168.0, 167.5, 165.7 (d, J = 256.0 Hz), 151.7, 141.4, 140.7, 138.0, 137.3, 134.9, 132.1 (d, J = 9.4 Hz), 131.8, 131.4 (d, J = 2.7 Hz), 124.2, 123.5, 123.2, 117.5, 115.7 (d, J = 21.9 Hz), 51.0, 50.3, 29.0, 28.7; HRMS (EI, [M+H]⁺) for C₂₄H₂₀FN₂O_{4⁺} calcd. 419.1402, found 419.1402.



5-(1-(Azulen-1-yl)-2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)-1,3-dimethylpyrimidine-

2,4,6(1*H***,3***H***,5***H***)-trione (4i). Yield: 181 mg, 97% (Procedure A, 0.4 mmol scale); black-blue solid; mp: 147-148°C; ¹H NMR (400 MHz, CDCl₃) \delta 8.53 (d,** *J* **= 9.7 Hz, 1H), 8.35 (d,** *J* **= 9.4 Hz, 1H), 7.78 (d,** *J* **= 8.1 Hz, 2H), 7.75 – 7.67 (m, 1H), 7.62 (d,** *J* **= 4.0 Hz, 1H), 7.49 (d,** *J* **= 8.3 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.30 – 7.23 (m, 2H), 6.44 (d,** *J* **= 2.7 Hz, 1H), 3.90 (d,** *J* **= 2.8 Hz, 1H), 3.34 (s, 3H), 3.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 197.6, 167.8, 167.4, 151.6, 141.4, 140.5, 138.1, 137.9, 137.4, 135.1, 134.5 (q,** *J* **= 32.7 Hz), 131.9, 129.6, 125.6 (q,** *J* **= 3.6 Hz), 124.4, 123.5 (q,** *J* **= 273.0 Hz), 123.3, 122.7, 117.6, 51.0, 50.3, 29.0, 28.7; HRMS (EI, [M+Na]⁺) for C₂₅H₁₉F₃N₂O₄Na⁺ calcd. 491.1189, found 491.1189.**



4-(2-(Azulen-1-yl)-2-(1,3-dimethyl-2,4,6-trioxohexahydropyrimidin-5-yl)acetyl)benzonitrile (**4j**). Yield: 31 mg, 58% (Procedure A, 0.125 mmol scale); black-blue solid; mp: 101-103°C; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 9.7 Hz, 1H), 8.33 (d, *J* = 9.4 Hz, 1H), 7.77 – 7.66 (m, 3H), 7.59 (d, *J* = 3.9 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.38 – 7.22 (m, 3H), 6.40 (d, *J* = 2.5 Hz, 1H), 3.92 (d, *J* = 2.5 Hz, 1H), 3.32 (s, 3H), 3.29 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.3, 167.7, 167.3, 151.5, 141.5, 140.4, 138.4, 138.2, 137.5, 135.2, 132.3, 131.9, 129.6, 124.5, 123.4, 122.3, 117.8, 117.6, 116.4, 51.0, 50.1, 29.0, 28.7; HRMS (EI, [M+Na]⁺) for C₂₅H₁₉N₃O₄Na⁺ calcd. 448.1268, found 448.1259.



5-(1-(Azulen-1-yl)-2-(4-methoxyphenyl)-2-oxoethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4k).** Yield: 66 mg, 77% (Procedure A, 0.2 mmol scale); dark blue solid; mp: 105-107°C; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 9.7 Hz, 1H), 8.32 (d, *J* = 9.3 Hz, 1H), 7.72 – 6.62 (m, 4H), 7.34

-7.19 (m, 3H), 6.68 (d, J = 9.0 Hz, 2H), 6.42 (d, J = 2.7 Hz, 1H), 3.78 (d, J = 2.8 Hz, 1H), 3.73 (s, 3H), 3.34 (s, 3H), 3.32 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 196.9, 168.2, 167.7, 163.7, 151.8, 141.4, 140.8, 137.8, 137.1, 134.7, 131.83, 131.76, 127.9, 124.4, 124.0, 123.0, 117.4, 113.7, 55.5, 51.0, 50.4, 29.0, 28.6; HRMS (EI, [M+H]⁺) for C₂₅H₂₃N₂O₅⁺ calcd. 431.1601, found 431.1596.



5-(1-(Azulen-1-yl)-2-(4-(dimethylamino)phenyl)-2-oxoethyl)-1,3-dimethylpyrimidine-

2,4,6(1*H*,3*H*,5*H*)-trione (4l). Yield: 105 mg, 59% (Procedure A, 0.4 mmol scale); grey blue solid; mp: 191-193°C; ¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, *J* = 9.7 Hz, 1H), 8.31 (d, *J* = 9.3 Hz, 1H), 7.71 (d, *J* = 3.9 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.57 (d, *J* = 9.1 Hz, 2H), 7.33 – 7.16 (m, 3H), 6.44 – 6.35 (m, 3H), 3.72 (d, *J* = 2.8 Hz, 1H), 3.34 (s, 3H), 3.32 (s, 3H), 2.94 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 195.9, 168.4, 167.9, 153.5, 151.9, 141.5, 141.1, 137.6, 136.9, 134.6, 131.8, 131.7, 125.5, 123.8, 122.7, 122.6, 117.4, 110.5, 51.1, 50.3, 39.9, 28.9, 28.6; HRMS (EI, [M+Na]⁺) for C₂₆H₂₅N₃O₄Na⁺ calcd. 466.1737, found 466.1733.



5-(1-(Azulen-1-yl)-2-oxo-2-(o-tolyl)ethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4m). Yield: 141 mg, 81% (Procedure A, 0.42 mmol scale); purple solid; mp: 132-134°C; ¹H NMR (400 MHz, CDCl₃) \delta 8.37 (d,** *J* **= 9.2 Hz, 1H), 8.16 (d,** *J* **= 8.7 Hz, 1H), 7.64 – 7.44 (m, 2H), 7.33 – 6.99 (m, 6H), 6.87 – 6.71 (m, 1H), 6.31 (s, 1H), 3.85 (s, 1H), 3.22 (s, 3H), 3.17 (s, 3H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 202.1, 168.0, 167.8, 151.6, 141.2, 140.2, 139.0, 137.8, 137.0, 136.0, 135.5, 132.0, 131.9, 131.6, 128.9, 125.5, 123.9, 123.4, 123.0, 117.4, 51.6, 51.1, 28.9, 28.7, 21.3; HRMS (EI, [M+Na]⁺) for C₂₅H₂₂N₂O₄Na⁺ calcd. 437.1472, found 437.1472.**



5-(1-(Azulen-1-yl)-2-oxo-2-(thiophen-2-yl)ethyl)-1,3-dimethylpyrimidine-2,4,6(1*H***,3***H***,5***H***)-trione (4n**). Yield: 274 mg, 84% (Procedure A, 0.8 mmol scale); black-blue solid; mp: 99-101°C; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 9.7 Hz, 1H), 8.36 (d, *J* = 9.3 Hz, 1H), 7.88 (d, *J* = 3.5 Hz, 1H), 7.74 – 7.63 (m, 1H), 7.47 (d, *J* = 4.5 Hz, 1H), 7.38 – 7.21 (m, 3H), 7.11 (d, *J* = 3.1 Hz, 1H), 6.81 (t, *J* = 4.1 Hz, 1H), 6.32 (d, *J* = 1.3 Hz, 1H), 3.82 (d, *J* = 1.4 Hz, 1H), 3.34 (s, 3H), 3.30 (s, 3H); ¹³C NMR (100 MHz, 100 MHz, 100 MHz, 100 MHz).

CDCl₃) δ 191.2, 167.9, 167.5, 151.6, 141.6, 141.5, 140.8, 138.0, 137.3, 135.6, 134.6, 134.4, 132.0, 128.1, 124.2, 123.8, 123.3, 117.5, 51.1, 51.0, 29.0, 28.7; HRMS (EI, [M+Na]⁺) for C₂₂H₁₈N₂O₄SNa⁺ calcd. 429.0829, found 429.0827.



2-(1-(Azulen-1-yl)-2-(4-fluorophenyl)-2-oxoethyl)-3-hydroxycyclohex-2-en-1-one (40). Yield: 140 mg, 62% (Procedure A, 0.6 mmol scale); dark blue solid ; mp: 182-184°C; ¹H NMR (400 MHz, CDCl₃) δ 10.93 (s, 1H), 8.39 (d, J = 9.7 Hz, 1H), 8.34 – 8.25 (m, 3H), 7.89 (d, J = 3.9 Hz, 1H), 7.63 – 7.54 (m, 1H), 7.34 (m, 1H), 7.30 (d, J = 3.9 Hz, 1H), 7.21 – 7.10 (m, 4H), 2.59 – 2.31 (m, 4H), 1.99 – 1.78 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 203.8, 197.2, 177.2, 166.8 (d, J = 257.4 Hz), 141.3, 138.2, 137.3, 136.7, 136.4, 134.2, 132.6 (d, J = 9.7 Hz), 132.4 (d, J = 2.9 Hz), 124.3, 123.4, 123.2, 117.0, 116.3 (d, J = 22.0 Hz), 113.5, 39.6, 36.8, 30.6, 20.4; HRMS (EI, [M+Na]⁺) for C₂₄H₁₉FO₃Na⁺ calcd. 397.1210, found 397.1210.



3-(1-(1,3-Dimethyl-2,4,6-trioxohexahydropyrimidin-5-yl)-2-oxo-2-phenylethyl)azulene-1-

carbaldehyde (**4p**). Yield: 240 mg, 56% (Procedure A, 1 mmol scale); dark red solid; mp: 178-180°C; ¹H NMR (400 MHz, CDCl₃) δ 10.18 (s, 1H), 9.66 (d, *J* = 9.6 Hz, 1H), 8.73 (d, *J* = 9.9 Hz, 1H), 8.04 (s, 1H), 8.01 – 7.89 (m, 1H), 7.77 – 7.62 (m, 4H), 7.50 – 7.39 (m, 1H), 7.32 – 7.20 (m, 2H), 6.40 (d, *J* = 2.4 Hz, 1H), 3.80 (d, *J* = 2.4 Hz, 1H), 3.37 (s, 3H), 3.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.9, 187.1, 167.9, 167.4, 151.5, 146.3, 141.0, 140.7, 140.3, 138.6, 134.7, 134.2, 133.9, 130.8, 129.3, 128.7, 128.6, 124.9, 124.8, 50.3, 49.6, 29.1, 28.7; HRMS (EI, [M+H]⁺) for C₂₅H₂₁N₂O₅⁺ calcd. 429.1445, found 429.1445.



Ethyl 3-(1-(2-hydroxy-6-oxocyclohex-1-en-1-yl)-2-oxo-2-phenylethyl)azulene-1-carboxylate (4q). Yield: 247 mg, 96% (Procedure B, 0.6 mmol scale); dark purple solid; mp: 88-100°C; ¹H NMR (400 MHz, CDCl₃) δ 11.07 (s, 1H), 9.63 (d, *J* = 10.0 Hz, 1H), 8.55 (d, *J* = 9.7 Hz, 1H), 8.33 (s, 1H), 8.31 – 8.24 (m, 2H), 7.83 – 7.74 (m, 1H), 7.67 – 7.59 (m, 1H), 7.55 – 7.47 (m, 3H), 7.47 – 7.39 (m, 1H), 7.34 (s, 1H), 4.40 (q, *J* = 7.1 Hz, 2H), 2.59 – 2.32 (m, 4H), 1.99 – 1.76 (m, 2H), 1.43 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 205.2, 197.1, 177.6, 165.3, 141.7, 141.1, 139.7, 139.4, 138.1, 135.8, 135.7, 134.9, 129.8, 129.2, 128.1, 127.0, 124.0, 115.7, 113.2, 60.0, 39.2, 36.8, 30.6, 20.4, 14.8; HRMS (EI, [M+Na]⁺) for C₂₇H₂₄O₅Na⁺ calcd. 451.1516, found 451.1510.



Ethyl 3-(1-(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)-2-oxo-2-phenylethyl)azulene-1carboxylate (4r). Yield: 165 mg, 90% (Procedure B, 0.4 mmol scale); dark purple solid ; mp: 88-89°C; ¹H NMR (400 MHz, CDCl₃) δ 10.80 (bs, 1H), 9.63 (d, *J* = 9.9 Hz, 1H), 8.52 (d, *J* = 9.7 Hz, 1H), 8.32 (s, 1H), 8.30 – 8.24 (m, 2H), 7.83 – 7.74 (m, 1H), 7.67 – 7.59 (m, 1H), 7.55 – 7.47 (m, 3H), 7.45 – 7.37 (m, 1H), 7.28 (s, 1H), 4.44 – 4.35 (m, 2H), 2.43 (d, *J* = 17.8 Hz, 1H), 2.38 – 2.24 (m, 4H), 1.43 (t, *J* = 7.1 Hz, 3H), 1.02 (s, 3H), 0.89 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 205.0, 196.8, 175.9, 165.3, 141.8, 141.1, 139.7, 139.4, 138.1, 135.80, 135.77, 134.9, 129.7, 129.2, 128.1, 126.9, 124.0, 115.7, 112.3, 60.0, 50.5, 44.1, 39.2, 31.6, 29.5, 26.9, 14.8; HRMS (EI, [M+Na]⁺) for C₂₇H₂₈O₅Na⁺ calcd. 479.1829, found 479.1821.



Ethyl 3-(1-(5-hydroxy-3-oxo-1,2,3,6-tetrahydro-[1,1'-biphenyl]-4-yl)-2-oxo-2-phenylethyl)azulene-1-carboxylate (4s). Yield: 33 mg, 44% (Procedure B, 0.15 mmol scale, the product was washed with pentane after column chromatography); dark purple solid; mp: 87-89°C; in NMR, observed as as a mixture of two interconvertible diastereomeric enol forms (dr = 2:1); ¹H NMR (400 MHz, CDCl₃) δ 11.44 (bs, 0.67H), 10.93 (bs, 0.33H), 9.75 – 9.55 (m, 1H), 8.66 (d, J = 9.7 Hz, 0.67H), 8.49 (d, J = 9.6 Hz, 0.33H), 8.39 (s, 0.67H), 8.34 (s, 0.33H), 8.32 – 8.20 (m, 2H), 7.86 – 7.71 (m, 1H), 7.68 – 7.01 (m, 11H), 4.49 – 4.33 (m, 2H), 3.44 – 3.30 (m, 0.33H), 3.27 – 3.10 (s, 0.67H), 2.90 – 2.52 (m, 4H), 1.49 – 1.37 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 205.4, 204.7, 196.3, 196.0, 176.8, 176.2, 165.3, 142.5, 142.4, 141.7, 141.2, 141.1, 139.8, 139.6, 139.4, 138.2, 138.1, 135.79, 135.76, 134.93, 134.85, 129.8, 129.7, 129.2, 128.9, 128.7, 128.2, 128.1, 127.2, 127.10, 127.07, 127.0, 126.74, 126.70, 123.9, 123.7, 115.9, 115.8, 113.2, 113.1, 60.03, 59.99, 43.8, 43.6, 39.4, 39.2, 38.3, 38.1, 37.3, 14.8; HRMS (EI, [M+Na]⁺) for C₃₃H₂₈O₅Na⁺ calcd. 527.1829, found 527.1816.

General procedure for the synthesis of azulene-tetrahydrocinnolin-5-one conjugates 5a,5b from azulene-containing MCR adducts 4c,4d

Azulene derivative **4c,d** (0.4 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in methanol (2 mL) followed by addition of hydrazine monohydrate (20 mg, 0.4 mmol, 1 equiv). The reaction mixture was stirred for 24h at room temperature. The reaction progress was monitored by TLC. After completion of reaction, the mixture was diluted with CH_2Cl_2 and evaporated with silica gel under reduced pressure. Column chromatography with $CH_2Cl_2/EtOAc$ (19:1) as eluent delivered azulene-tetrahydrocinnolin-5-one conjugate **5a**. For the isolation of product **5b**, pure CH_2Cl_2 was used as an eluent.



4-(**Azulen-1-yl**)-**3**-phenyl-**4**,**6**,**7**,**8**-tetrahydrocinnolin-5(1*H*)-one (**5**a). Yield: 132 mg, 94%; blue solid; mp: 236-238°C; ¹H NMR (400 MHz, [D₆]DMSO) δ 10.96 (s, 1H), 9.02 (d, *J* = 9.8 Hz, 1H), 8.28 (d, *J* = 9.3 Hz, 1H), 7.75 – 7.62 (m, 3H), 7.49 (d, *J* = 3.8 Hz, 1H), 7.35 – 7.19 (m, 5H), 7.19 – 7.11 (m, 1H), 5.77 (s, 1H), 2.56 – 2.48 (m, 2H, overlaps with the signal of [D₆]DMSO), 2.31 – 2.09 (m, 2H), 1.94 – 1.82 (m, 1H), 1.70 – 1.55 (m, 1H); ¹³C NMR (100 MHz, [D₆]DMSO) δ 193.9, 150.1, 147.0, 140.5, 138.1, 136.9, 136.2, 136.1, 134.8, 133.2, 132.0, 128.9, 128.4, 125.8, 122.7, 122.6, 117.3, 104.6, 36.7, 27.7, 24.5, 20.6; HRMS (EI, [M+Na]⁺) for C₂₄H₂₀N₂ONa⁺ calcd. 375.1468, found 375.1464.



4-(**Azulen-1-yl**)-**8**,**8**-dimethyl-3-phenyl-4,**6**,**7**,**8**-tetrahydrocinnolin-5(1*H*)-one (5b). Yield: 141 mg, 93%; blue solid; mp: 199-202°C; ¹H NMR (400 MHz, [D₆]DMSO) δ 10.92 (s, 1H), 8.96 (d, *J* = 9.8 Hz, 1H), 8.27 (d, *J* = 9.3 Hz, 1H), 7.78 – 7.70 (m, 2H), 7.70 – 7.62 (m, 1H), 7.54 (d, *J* = 3.8 Hz, 1H), 7.35 – 7.19 (m, 5H), 7.19 – 7.10 (m, 1H), 5.74 (s, 1H), 2.45 (d, *J* = 16.7 Hz, 1H), 2.30 (d, *J* = 16.5 Hz, 1H), 2.20 (d, *J* = 16.1 Hz, 1H), 1.94 (d, *J* = 16.4 Hz, 1H), 1.00 (s, 3H), 0.67 (s, 3H); ¹³C NMR (100 MHz, [D₆]DMSO) δ 193.4, 148.4, 147.0, 140.5, 138.0, 136.9, 136.2, 136.1, 134.8, 133.1, 131.9, 128.9, 128.3, 125.8, 122.7, 122.6, 117.3, 103.4, 50.3, 37.7, 32.2, 29.0, 27.7, 26.1; HRMS (EI, [M+Na]⁺) for C₂₆H₂₄N₂ONa⁺ calcd. 403.1781, found 403.1774.

Synthesis of azulene-dihydroindol-4-one conjugates 7 from azulene-containing MCR adducts 4



3-(**Azulen-1-yl**)-**1**,**2**-diphenyl-**1**,**5**,**6**,**7**-tetrahydro-4*H*-indol-4-one (7a). Azulene-containing adduct 4c (36 mg, 0.1 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of aniline (14 mg, 0.15 mmol, 1.5 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 6 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (7:1) as eluent delivered azulene-dihydroindol-4-one conjugate 7a. Yield: 37 mg, 89%; dark blue solid; mp: 191-192°C; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 9.3 Hz, 1H), 8.03 (d, *J* = 9.8 Hz, 1H), 7.84 (d, *J* = 3.8 Hz, 1H), 7.45 – 7.31 (m, 5H), 7.25 – 7.14 (m, 2H), 7.07 – 6.98 (m, 1H), 6.96 – 6.82 (m, 4H), 6.79 – 6.72 (m, 2H), 2.88 – 2.69 (m, 2H), 2.60 – 2.47 (m, 2H), 2.26 – 2.14 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.7, 145.0, 141.5, 140.0, 137.9, 137.1, 136.13, 136.11, 136.07, 133.8, 131.8, 130.4, 129.2, 128.2, 128.1, 127.8, 126.6, 123.2, 122.5, 122.0, 119.7, 117.0, 116.8, 39.2, 23.8, 23.6; HRMS (EI, [M+H]⁺) for C₃₀H₂₄NO⁺ calcd. 414.1852, found 414.1843.



3-(**Azulen-1-yl**)-**6**,**6**-dimethyl-1,**2**-diphenyl-1,**5**,**6**,**7**-tetrahydro-4*H*-indol-4-one (7b). Azulenecontaining adduct **4d** (38 mg, 0.1 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of aniline (10 mg, 0.11 mmol, 1.1 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 8 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (17:3) as eluent delivered azulene-dihydroindol-4-one conjugate 7b. Yield: 21 mg, 48%; dark blue solid; mp: 238-240°C; ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 9.3 Hz, 1H), 8.03 (d, *J* = 9.7 Hz, 1H), 7.87 (d, *J* = 3.8 Hz, 1H), 7.45 – 7.33 (m, 5H), 7.26 – 7.13 (m, 2H), 7.07 – 6.99 (m, 1H), 6.97 – 6.83 (m, 4H), 6.80 – 6.74 (m, 2H), 2.66 (bs, 2H), 2.44 (s, 2H), 1.20 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 193.2, 143.8, 141.5, 140.1, 137.8, 137.1, 136.1, 136.0, 133.9, 131.8, 130.3, 129.2, 128.17, 128.15, 127.7, 126.5, 123.1, 122.5, 122.0, 118.5, 117.0, 116.6, 53.2, 37.6, 35.1, 28.8; HRMS (EI, [M+Na]⁺) for C₃₂H₂₇NONa⁺ calcd. 464.1985, found 464.1985.



3-(Azulen-1-yl)-2-(4-fluorophenyl)-1-phenyl-1,5,6,7-tetrahydro-4*H***-indol-4-one (7c). Azulenecontaining adduct 4o** (150 mg, 0.4 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (2 mL) followed by addition of aniline (56 mg, 0.6 mmol, 1.5 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 8 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (9:1 \rightarrow 17:3) as eluent followed by washing with pentane delivered azulene-dihydroindol-4-one conjugate **7c**. Yield: 108 mg, 63%; dark blue solid; mp: 180-182°C; ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 9.3 Hz, 1H), 7.99 (d, *J* = 9.7 Hz, 1H), 7.82 (d, *J* = 3.8 Hz, 1H), 7.46 – 7.32 (m, 5H), 7.26 – 7.10 (m, 2H), 7.08 – 7.00 (m, 1H), 6.92 – 6.83 (m, 1H), 6.75 – 6.67 (m, 2H), 6.63 – 6.54 (m, 2H), 2.87 – 2.66 (m, 2H), 2.58 – 2.48 (m, 2H), 2.25 – 2.13 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.8, 161.5 (d, *J* = 246.9 Hz), 145.0, 141.6, 140.0, 137.7, 137.2, 136.2, 136.1, 136.0, 132.7, 132.0 (d, *J* = 8.0 Hz), 129.3, 128.3, 128.1, 127.9 (d, *J* = 3.2 Hz), 123.0, 122.7, 122.1, 119.7, 117.1, 117.0, 114.9 (d, *J* = 21.5 Hz), 39.2, 23.8, 23.6; HRMS (EI, [M+H]⁺) for C₃₀H₂₃FNO⁺ calcd. 432.1758, found 432.1754.



3-(Azulen-1-yl)-1-(3-chlorophenyl)-2-phenyl-1,5,6,7-tetrahydro-4*H*-indol-4-one (7d). Azulenecontaining adduct **4c** (71 mg, 0.2 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of 3-chloroaniline (28 mg, 0.22 mmol, 1.1 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 24 h. For the next purification steps, three batches of 0.2 mmol scale were combined together. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (9:1 \rightarrow 17:3) as eluent followed by washing with pentane delivered azulene-dihydroindol-4-one conjugate **7d**. Yield: 94 mg, 35% (combined yield for three reactions on 0.2 mmol scale); dark blue solid; mp: 188-190°C; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 9.3 Hz, 1H), 7.99 (d, *J* = 9.7 Hz, 1H), 7.81 (d, *J* = 3.1 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.36 – 7.31 (m, 2H), 7.31 – 7.25 (m, 2H), 7.08 – 6.99 (m, 2H), 6.99 – 6.82 (m, 4H), 6.78 – 6.72 (m, 2H), 2.87 – 2.71 (m, 2H), 2.58 – 2.49 (m, 2H), 2.26 – 2.16 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.6, 144.8, 141.5, 140.0, 139.0, 137.1, 136.18, 136.15, 136.0, 134.7, 133.7, 131.3, 130.3, 130.2, 128.5, 128.2, 127.9, 126.9, 126.5, 122.9, 122.6, 122.1, 119.9, 117.2, 117.1, 39.1, 23.8, 23.6; HRMS (EI, [M+Na]⁺) for C₃₀H₂₂ClNONa⁺ calcd. 470.1282, found 470.1282.



3-(Azulen-1-yl)-1-(3,5-dimethoxyphenyl)-2-phenyl-1,5,6,7-tetrahydro-4*H*-indol-4-one (7e). Azulene-containing adduct **4c** (143 mg, 0.4 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (2 mL) followed by addition of 3,5-dimethoxyaniline (92 mg, 0.6 mmol, 1.5 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 8 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (9:1→4:1) as eluent delivered azulene-dihydroindol-4-one conjugate **7e**. Yield: 107 mg, 56%; dark blue solid; mp: 250-252°C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 9.3 Hz, 1H), 8.01 (d, *J* = 9.7 Hz, 1H), 7.83 (d, *J* = 3.8 Hz, 1H), 7.44 – 7.36 (m, 1H), 7.33 (d, *J* = 3.8 Hz, 1H), 7.06 – 6.98 (m, 1H), 6.98 – 6.89 (m, 3H), 6.89 – 6.78 (m, 3H), 6.42 (t, *J* = 2.2 Hz, 1H), 6.32 (bs, 2H), 3.66 (s, 6H), 2.91 – 2.76 (m, 2H), 2.58 – 2.47 (m, 2H), 2.26 – 2.14 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.7, 160.9, 144.9, 141.6, 140.1, 139.4, 137.1, 136.14, 136.11, 136.09, 133.7, 132.0, 130.2, 127.8, 126.7, 123.2, 122.5, 122.0, 119.7, 117.0, 116.8, 106.6, 100.3, 55.6, 39.2, 23.9, 23.7; HRMS (EI, [M+H]⁺) for C₃₂H₂₇NO₃⁺ calcd. 474.2064, found 474.2064.



3-(Azulen-1-yl)-1-(4-methoxybenzyl)-2-phenyl-1,5,6,7-tetrahydro-4H-indol-4-one (7f). Azulenecontaining adduct **4c** (71 mg, 0.2 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of 4-methoxybenzylamine (41 mg, 0.3 mmol, 1.5 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 8 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (9:1 \rightarrow 17:3) as eluent delivered azulene-dihydroindol-4-one conjugate **7f**. Yield: 78 mg, 85%; blue solid; mp: 159-161°C; ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 9.3 Hz, 1H), 7.99 (d, *J* = 9.7 Hz, 1H), 7.76 (d, *J* = 3.8 Hz, 1H), 7.44 – 7.35 (m, 1H), 7.28 (d, *J* = 3.9 Hz, 1H), 7.13 – 7.03 (m, 3H), 7.03 – 6.96 (m, 3H), 6.94 (d, *J* = 8.7 Hz, 2H), 6.91 – 6.83 (m, 3H), 5.09 (s, 2H), 3.82 (s, 3H), 2.83 – 2.71 (m, 2H), 2.56 – 2.44 (m, 2H), 2.24 – 2.13 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.5, 159.1, 144.2, 141.4, 139.9, 137.0, 136.12, 136.05, 136.03, 134.1, 132.0, 130.7, 129.5, 128.3, 127.6, 127.2, 123.5, 122.4, 121.9, 119.5, 116.9, 116.5, 114.5, 55.4, 47.7, 39.1, 23.6, 23.0; HRMS (EI, [M+H]⁺) for C₃₂H₂₈NO₂⁺ calcd. 458.2115, found 458.2115.



3-(Azulen-1-yl)-2-phenyl-1-(4-(trifluoromethyl)benzyl)-1,5,6,7-tetrahydro-4*H*-indol-4-one (7g). Azulene-containing adduct **4c** (71 mg, 0.2 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of (4-(trifluoromethyl)phenyl)methanamine (39 mg, 0.22 mmol, 1.1 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 5 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (4:1 \rightarrow 7:3) as eluent delivered azulene-dihydroindol-4-one conjugate **7g**. Yield: 92 mg, 93%; dark blue solid; mp: 148-150°C; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 9.3 Hz, 1H), 8.00 (d, *J* = 9.7 Hz, 1H), 7.77 (d, *J* = 3.9 Hz, 1H), 7.63 (d, *J* = 8.1 Hz, 2H), 7.46 – 7.36 (m, 1H), 7.29 (d, *J* = 3.9 Hz, 1H), 7.17 – 6.94 (m, 8H), 6.93 – 6.85 (m, 1H), 5.19 (s, 2H), 2.80 – 2.68 (m, 2H), 2.57 – 2.45 (m, 2H), 2.26 – 2.14 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 193.4, 143.9, 141.65, 141.64, 141.5, 139.9, 137.1, 136.2, 136.1, 135.9, 134.1, 131.6, 130.6, 130.1 (d, *J* = 32.6 Hz), 128.5, 127.8, 126.24, 126.15 (q, *J* = 3.7 Hz), 124.1 (q, *J* = 272.0 Hz), 123.1, 122.6, 122.0, 119.8, 117.0, 116.9, 47.8, 39.0, 23.5, 22.9; HRMS (EI, [M+H]⁺) for C₃₂H₂₅F₃NO⁺ calcd. 496.1883, found 496.1883.



3-(Azulen-1-yl)-1-(4-chlorobenzyl)-6,6-dimethyl-2-phenyl-1,5,6,7-tetrahydro-4*H***-indol-4-one (7h). Azulene-containing adduct 4d** (77 mg, 0.2 mmol, 1 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of (4-chlorophenyl)methanamine (31 mg, 0.22 mmol, 1.1 equiv). The mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 4.5 h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (17:3) as eluent followed by washing with pentane delivered azulene-dihydroindol-4-one conjugate **7h**. Yield: 71 mg, 72%; blue solid; mp: 190-192°C; ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 9.3 Hz, 1H), 7.96 (d, *J* = 9.7 Hz, 1H), 7.76 (d, *J* = 3.9 Hz, 1H), 7.44 – 7.36 (m, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.28 (d, *J* = 3.9 Hz, 1H), 7.13 – 6.90 (m, 8H), 6.90 – 6.82 (m, 1H), 5.10 (s, 2H), 2.61 (s, 2H), 2.40 (s, 2H), 1.15 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 192.9, 142.9, 141.5, 139.9, 137.1, 136.2, 136.1, 136.0, 134.2, 133.5, 131.8, 130.6, 129.3, 128.4, 127.7, 127.2, 123.1, 122.5, 122.0, 118.5, 117.0, 116.6, 53.2, 47.5, 36.8, 35.3, 28.8; HRMS (EI, [M+H]⁺) for C₃₃H₂₉ClNO⁺ calcd. 490.1932, found 490.1932.

One-pot synthesis of azulene-dihydroindol-4-one conjugate 7a

Phenylglyoxal monohydrate (**2a**, 46 mg, 0.3 mmol, 1.5 equiv) was placed in a screw-capped vial and dissolved in *i*PrOH (1 mL) followed by addition of azulene (**1a**, 26 mg, 0.2 mmol, 1 equiv) and cyclohexane-1,3-dione (**3c**, 45 mg, 0.4 mmol, 2 equiv). The resulting mixture was sealed, placed in an oil bath preheated at 80 °C and stirred for 1h. Upon completion of this time, the aniline (**6a**, 41 mg, 0.44 mmol, 2.2 equiv) was added and the reaction was continued for another 8h. The resulting mixture was diluted with EtOAc and evaporated with silica gel under reduced pressure. Column chromatography with petroleum ether/EtOAc (17:3) as eluent delivered azulene-dihydroindol-4-one conjugate **7a**.

UV/vis absorption spectra

The UV/Vis absorption was measured in dichloromethane and in methanol at $c \approx 5 \cdot 10^{-6}$ M.










































































































